Compare Redwire Corporation (RDW) vs TG Therapeutics Inc (TGTX) Price & Performance

RDW trades at $9.58, down 6.45% today, with technical indicators showing bearish momentum despite oversold RSI readings near 27. The company reported significant losses with a -57.26% net income margin and negative cash flow from operations, though revenue grew to $335M in 2025. Recent Space Force contract wins and partnerships highlight growth potential in defense and space infrastructure markets.

While analyst consensus remains bullish with an 80% buy rating and $14.88 price target, RDW faces substantial execution risks from persistent losses and dependence on SpaceX's Starship success. The stock offers high-risk exposure to the growing space economy but requires careful monitoring of profitability improvements and contract execution.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.